Discontinued — last reported Q4 '25
Humana Cash, Cash Equivalents, and Marketable Securities increased by 35.9% to $15.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.6%, from $14.38B to $15.05B. Over 3 years (FY 2022 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows a downward trend with a -6.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
A standard liquidity metric reported by virtually all public companies on the balance sheet.
cash_equivalents_marketable_securities_total| Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.38B | $12.76B | $14.97B | $14.67B | $15.27B | $15.55B | $11.38B | $16.30B | $14.38B | $12.98B | $11.75B | $11.07B | $15.05B |
| QoQ Change | — | -4.6% | +17.3% | -2.0% | +4.1% | +1.8% | -26.8% | +43.2% | -11.8% | -9.7% | -9.5% | -5.8% | +35.9% |
| YoY Change | — | — | — | +9.6% | +19.6% | +3.9% | — | +11.1% | -5.8% | -16.5% | +3.2% | -32.1% | +4.6% |